MRSN stock touches 52-week low at $0.56 amid market challenges
Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a new 52-week low, trading at $0.56, as the biopharmaceutical ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Target Price from Analysts
Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...
bovnews3d
What’s Fueling Mersana Therapeutics Inc (MRSN) Stock’s -75.00% Loss Below Its 200-Day SMA?
Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $0.53 which represents a decrease of $-0.02 or -3.64% from the prior close of $0.55. The stock opened at $0.54 and touched a low ...
Mersana Therapeutics' chief accounting officer sells shares worth $2,061
On January 15, Ashish Mandelia, Vice President and Chief Accounting Officer at Mersana Therapeutics, Inc. (NASDAQ:MRSN), a ...
Yahoo Finance16d
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated, with no ...
Mersana falls after early-stage trial data for lead cancer therapy
Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...
bovnews13d
MRSN’s Latest Twist: What’s Fueling the Unexpected Shifts in Mersana Therapeutics Inc’s Stock Price?
Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $0.72 which represents a decrease of $-0.58 or -44.62% from the prior close of $1.3. The stock opened at $1.07 and touched a low ...
Mersana Therapeutics: Promising Clinical Data and Strong Financial Position Justify Buy Rating
Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...
Yahoo Finance3d
Mersana Therapeutics, Inc. (MRSN)
On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...
Business Insider15d
Buy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price Volatility
Begin your TipRanks Premium journey today. Mersana Therapeutics (MRSN) Company Description: Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve ...
Nasdaq16d
Mersana Therapeutics Receives Additional FDA Fast Track Designation for XMT-1660 in Advanced Breast Cancer Treatment
Mersana Therapeutics, Inc. announced that the FDA has granted an additional Fast Track designation for its drug XMT-1660, also known as emiltatug ledadotin (Emi-Le), aimed at treating advanced or ...
Nasdaq16d
Mersana Therapeutics Reports Positive Phase 1 Results for Emiltatug Ledadotin in Triple-Negative Breast Cancer
Mersana Therapeutics has reported encouraging preliminary data from the Phase 1 trial of its lead antibody-drug conjugate, emiltatug ledadotin (Emi-Le), which targets B7-H4 in patients with ...